{"title":"贝兰他单-马福多汀在复发/难治性多发性骨髓瘤中的实际应用:系统回顾","authors":"Abdelrahman Nanah, Samer Al Hadidi","doi":"10.58877/japaj.v1i2.56","DOIUrl":null,"url":null,"abstract":"Belantamab mafodotin is an antibody drug conjugate directed against B-cell maturation antigen and was approved by the Food and Drug Administration under accelerated approval for use in the US in August 2020 for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. In November 2022 belantamab mafodotin was withdrawn from the US market after failure of a required confirmatory trial. In our review, we provide a systematic review on the use of belantamab mafodotin efficacy and safety in a real-world setting.","PeriodicalId":364383,"journal":{"name":"JAP Academy Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Real-World Use of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: A Systematic Review\",\"authors\":\"Abdelrahman Nanah, Samer Al Hadidi\",\"doi\":\"10.58877/japaj.v1i2.56\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Belantamab mafodotin is an antibody drug conjugate directed against B-cell maturation antigen and was approved by the Food and Drug Administration under accelerated approval for use in the US in August 2020 for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. In November 2022 belantamab mafodotin was withdrawn from the US market after failure of a required confirmatory trial. In our review, we provide a systematic review on the use of belantamab mafodotin efficacy and safety in a real-world setting.\",\"PeriodicalId\":364383,\"journal\":{\"name\":\"JAP Academy Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAP Academy Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.58877/japaj.v1i2.56\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAP Academy Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.58877/japaj.v1i2.56","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Real-World Use of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: A Systematic Review
Belantamab mafodotin is an antibody drug conjugate directed against B-cell maturation antigen and was approved by the Food and Drug Administration under accelerated approval for use in the US in August 2020 for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. In November 2022 belantamab mafodotin was withdrawn from the US market after failure of a required confirmatory trial. In our review, we provide a systematic review on the use of belantamab mafodotin efficacy and safety in a real-world setting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
